In this episode of MD Newsline, Dr. Iqra Aftab, a practicing rheumatologist specializing in complex autoimmune diseases, provides a comprehensive overview of the modern spondyloarthritis (SpA) spectrum. Dr. Aftab clarifies the umbrella concept of spondyloarthritis, detailing its subtypes—including psoriatic arthritis, IBD-associated arthritis, reactive arthritis, and ankylosing spondylitis—while dissecting the critical distinction between radiographic axial spa and non-radiographic axial spa. She addresses the rising incidence of mechanical back pain, highlighting key clinical red flags for inflammatory back pain in patients under age 45. The discussion explores practical application of the ACR 2026 guidelines, ASAS/SPARTAN criteria, and the EULAR 2026 imaging update, emphasizing the sequence of plane radiographs, MRI of the sacroiliac joints, and low-dose CT. Furthermore, Dr. Aftab outlines step-up treatment algorithms from NSAIDs to TNF inhibitors, IL-17 inhibitors, and JAK inhibitors, while emphasizing extra-articular manifestations (anterior uveitis, psoriasis, inflammatory bowel disease), patient self-advocacy, multidisciplinary care, and lifestyle interventions like exercise, physiotherapy, and smoking cessation. Episode Highlights Demystifying the Spondyloarthritis Spectrum Dr. Aftab breaks down spondyloarthritis as a family of inflammatory arthritides affecting the spine, tendons, and ligamentous insertions (entheses). She explains that the overarching umbrella encompasses psoriatic arthritis, reactive arthritis, IBD-associated arthritis, and axial spondyloarthritis. Within axial disease, she clarifies that ankylosing spondylitis is now formally categorized as radiographic axial spa, whereas disease lacking structural joint damage on plain films is classified as non-radiographic axial spa. Differentiating Inflammatory from Mechanical Back Pain While mechanical back pain improves with rest and worsens with activity, inflammatory back pain presents with severe morning stiffness (patients often describe feeling like a "tin man" or "tin woman") and improves significantly with exercise and anti-inflammatory medications. Dr. Aftab stresses that persistent symptoms in patients under age 45 should immediately raise clinical suspicion for axial spondyloarthritis regardless of initial radiographic findings. Navigating Diagnostic Delay and Extra-Articular Manifestations Diagnostic delays in axial spondyloarthritis frequently stretch from symptom onset to diagnosis, often taking up to five years. Clinicians must recognize extra-articular manifestations—including anterior uveitis in the eyes, psoriasis on the skin, and inflammatory bowel disease (ulcerative colitis or Crohn's disease) in the gut—rather than evaluating these systemic features in isolation. Imaging Modalities and Guideline Updates According to ACR 2026 guidelines and the EULAR 2026 imaging update, plane radiographs remain first-line imaging. When ordering x-rays, clinicians should request an anterior-posterior (AP) pelvis view specifically focusing on the sacroiliac joints rather than a standard lumbar spine view alone. If radiographs are normal, clinicians must order an MRI of the sacroiliac joints. Low-dose CT is primarily reserved for cases where MRI is unavailable or contraindicated. Dr. Aftab emphasizes that ASAS/SPARTAN classification criteria are designed for clinical trials and research populations, whereas individual clinical diagnosis requires holistic assessment. Therapeutic Algorithms: NSAIDs, Biologics, and Targeted Synthetics Initial therapy requires a full trial of NSAIDs, defined as two different anti-inflammatories at maximal dose for two to four weeks each (a total trial of four to eight weeks). If active disease persists, clinicians escalate treatment per ACR guidelines to TNF inhibitors or IL-17 inhibitors, both of which carry equal recommendation strength. JAK inhibitors are positioned later in the algorithm due to potential risks, including cardiovascular events, thromboembolic events, and malignancies. Comorbidity-Guided Treatment Selection and Tapering Co-existing conditions directly govern biologic choice: patients with recurrent uveitis or inflammatory bowel disease should receive monoclonal antibody TNF inhibitors (such as adalimumab or infliximab), whereas soluble receptors like etanercept are not indicated. While IL-17 inhibitors effectively target psoriasis, they must be used with caution as they can exacerbate underlying inflammatory bowel disease. When switching mechanisms, guidelines recommend moving to a different drug class after primary failure. For sustained remission, therapy should be gradually tapered by expanding dosing intervals rather than abrupt discontinuation to prevent rebound flares. Addressing Systemic Fatigue, Lifestyle, and Patient Advocacy Systemic fatigue in spondyloarthritis can stem directly from active autoimmune disease activity or secondary factors such as anemia, poor sleep architecture, and psychological distress. Non-pharmacologic management rests on exercise and physiotherapy as core therapeutic modalities, alongside aggressive smoking cessation, as active smoking correlates with heightened disease activity. Dr. Aftab encourages primary care clinicians to issue early referrals to rheumatology and urges patients to maintain strong self-advocacy throughout their diagnostic journey. Key Takeaway Normal plain radiographs do not rule out axial spondyloarthritis. Primary care clinicians should maintain a high index of suspicion for inflammatory back pain in young patients, ordering targeted sacroiliac joint MRI imaging and making early referrals to rheumatology to prevent years of unnecessary diagnostic delay, structural damage, and functional impairment. RESOURCES Website — https://mdnewsline.com/ Newsletter — https://mdnewsline.com/subscribe/ Dr Iqra Aftab — https://www.linkedin.com/in/iqra-a-206b2630/
